Company Profiles

driven by the PitchBook Platform

PeriGen

PeriGen
1995 FOUNDED
PRIVATE STATUS
71-80 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
5 INVESTORS
Description

Developer of fetal surveillance systems. The company focuses on reducing risk in obstetrics and care by developing fetal surveillance systems that utilize artificial intelligence (AI) and electronic health record (EHR) interfacing.

Website
Formerly Known As
E&C Medical Intelligence
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Monitoring Equipment
Other Industries
Decision/Risk Analysis
Primary Office
116 Village Boulevard
Suite 200
Princeton, NJ 08540
United States

+1 (877) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore PeriGen’s full profile, request a free trial.

PeriGen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 27-Sep-2016 0000 Completed Profitable
4. Convertible Debt 13-Mar-2014 000 0000 Completed Profitable
3. Later Stage VC (Series A1) 03-Apr-2013 00.000 0000 000.00 Completed Profitable
2. Later Stage VC (Series A) 27-Jan-2010 $4.58M $4.58M 0000 Completed Profitable
1. Buyout/LBO 19-Mar-2003 $4M 000 Completed Profitable
To view this company’s complete deal history including valuation and funding, request access »

PeriGen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A1 0,000,000 00.000000 00 00 00 00 00 00.000
Series A 00,000,000 00.000000 00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

PeriGen Investments & Acquisitions (2)

Company Name Date Type Deal Size Industry Lead Partner
0000-000 00000000 27-Sep-2016 000000000000000000 Monitoring Equipment 0000000 0000000
LMS Medical Systems 24-Jul-2009 Buyout/LBO 00.000 Outcome Management (Healthcare) 000000 000000 00.0
To view this company’s complete investment and acquisition history, request access »

PeriGen Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Ambina Partners Venture Capital Minority 000 0000 000000 0
Denali Ventures Venture Capital Minority 000 0000 000000 0
Salmon River Capital PE/Buyout Minority 000 0000 000000 0
Galen Partners PE/Buyout Majority 000 0000 000000 0
Trident Capital Venture Capital Majority 000 0000 000000 0

PeriGen Executive Team (13)

Name Title Board
Seat
Contact
Info
Matthew Sappern Chief Executive Officer
John Coats Chief Financial Officer & Controller
Brian Bishop Chief Product Officer
Emily Hamilton MD Senior Vice President of Clinical Research
Denise Queffelec Senior Vice President of Consulting Services

3 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

PeriGen Board Members (6)

Name Representing Role Since Contact
Info
David Jahns Galen Partners Board Member 000 0000
Greg Share Ambina Partners Chairman of the Board 000 0000
John Moragne Trident Capital Board Member 000 0000
John Reardon Trident Capital Chairman & Board Member 000 0000
Joshua Lewis Ph.D Salmon River Capital Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 6 board members. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com